Chemistry, Manufacturing, and Controls (CMC) Regulatory Consulting
Avoid clinical holds. Avoid delays. Get your CMC strategy right from day one.
Phase-Appropriate Global CMC Support from Early Development Through Commercialization
CMC gaps rarely show up when they're convenient, they surface during agency review, right before a marketing application, or worse, after a manufacturing change has already been made.
Veristat helps sponsors plan and document CMC programs for Pre-IND, IMPD, clinical development, marketing applications, and post-approval changes across regions. Our regulatory experts align manufacturing, analytical, and control strategies with the product’s stage of development and the requirements of each target market, supporting health authority interactions and submissions throughout the product lifecycle.
WHY VERISTAT
Reduce Regulatory Risk with Targeted CMC Expertise
CMC decisions affect more than manufacturing: gaps in product knowledge, controls, or documentation can lead to health authority questions, delays to clinical trial authorization, or challenges during marketing application review.
Planning early helps sponsors identify the evidence needed at each stage and prepare a coherent quality package as the program advances.
Veristat supports sponsors with CMC strategy, regulatory interactions, and submission content for investigational applications, including US INDs and the quality portions of IMPDs for clinical trial applications, as well as marketing applications and post-approval changes. We help teams build a consistent development story while addressing requirements specific to each region.
How It Works
CMC strategy isn't something you bolt on later, it has to move with your program from the very start. Here's how we help you stay ahead of it.
Plan early.
Starting at pre-IND, we map your CMC needs against the product, regulatory pathway, milestones, risks, and business considerations, well before a manufacturing plan is required.
Document it appropriately.
We help you generate the source documentation your IND or marketing application needs, since CMOs typically don't author regulatory submissions themselves.
Event One - 9AM EST
Engage the FDA.
We support every CMC-related FDA interaction, from Pre-IND meetings through multidisciplinary meetings, so nothing gets left to guesswork.
Manage change.
When your manufacturing process evolves, we guide comparability planning and help secure FDA buy-in, avoiding unnecessary bridging studies.
Veristat's Offerings
Veristat provides CMC expertise to help sponsors plan manufacturing and analytical programs, prepare quality documentation, and address regulatory expectations across global markets.
CMC Strategy and Development Planning.
Phase-appropriate CMC strategies and submission plans, from early clinical development through commercialization and post-approval.
Analytical and Stability Programs.
Planning for the analytical, characterization, and stability studies needed to support clinical development and marketing applications.
CMC Technical Writing.
Authoring and review of quality content for clinical trial applications, health authority briefing packages, marketing applications, and post-approval submissions, including IMPDs and CTD Modules 2.3 and 3.
Gap Analysis.
Assessment of CMC programs and submission content to identify risks, data needs, and region-specific requirements before key filing milestones.
Structured Data and Regional Submission Support.
Preparation of submission-ready CMC data, including chemical structure-data files for applicable US FDA submissions.
Health Authority Interaction Support.
CMC preparation, participation, and follow-up for meetings and written interactions with regulatory authorities in target markets.
Comparability and Change Management.
CMC change strategies and comparability planning to support process, site, and supply-chain evolution throughout development and after approval.
Team Augmentation.
Flexible CMC strategy and writing expertise to support internal teams during periods of high demand or at critical program milestones.
We bring practical regulatory CMC experience to each program, identifying potential challenges early and developing strategies to address them before they affect development timelines.
Clinical holds and regulatory delays can arise from gaps in CMC planning, even when the underlying science is sound. These gaps may be difficult to identify during day-to-day development and costly to address once they affect a submission. Veristat’s experience helps sponsors anticipate issues that commonly emerge in first-time clinical programs, contract manufacturing relationships, and comparability planning.
NEXT STEPS
What's Next in the Drug Development Process
Marketing Applications.
Move from CMC strategy to a complete, submission-ready marketing application.
Agency Meetings.
Prepare for Pre-IND, Type B, or other meetings where CMC content plays a role.
Medical Writing.
Get support authoring the Module 3 content and other documentation your CMC strategy depends on.
PROOF & RESOURCES
Real Programs, Real Outcomes
CMC Pitfalls, From Benchtop to IND.
Listen Now →
CMC Considerations for Planning Comparability Studies in Biotherapeutics.
Listen Now →
Overcoming a Partial Clinical Hold.
Learn More →
Know what your CMC data is telling you.
The right CMC decisions depend on seeing what your data means for the road ahead. Veristat brings regulatory and scientific expertise to your evidence to identify gaps, clarify requirements, and define what comes next, so each decision keeps your manufacturing and development strategy moving in the right direction.
Frequently Asked Questions
CMC regulatory planning should begin as early as the pre-IND stage and continue through the entire development lifecycle. While a manufacturing plan isn't a required component of an IND submission, mapping out analytical and clinical needs early helps sponsors avoid time delays and unexpected costs later.